In twelve patients affected by small bowel bacterial overgrowth, diagnosed by means of the lactulose hydrogen breath test, the therapeutic efficacy of a non-absorbable derivative of rifamycin, rifaximin, was evaluated. This study showed that this drug has a satisfactory therapeutic efficacy in contaminated small bowel syndrome and, at the doses tested, is free of side-effects.
IsaacsPETKimYS: The contaminated small bowel syndrome. Am J Med1979; 76: 1049–1057.
2.
RhodesJMMiddletonPJewellDP: The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. Scand J Gastroenterol1979; 14: 333–336.
3.
ThompsonDGO'BrienJDHardieJM: Influence of the oropharyngeal microflora on the measurement of exhaled breath hydrogen. Gastroenterology1986; 91: 853–860.
4.
KotlerDPHoltPRRosensweigNS: Modification of the breath hydrogen test: increased sensitivity for the detection of carbohydrate malabsorption. J Lab Clin Med1982; 100: 798–805.
5.
BiorneklettAFausaOMidtvedtT: Small-bowel bacterial overgrowth in the postgastrectomy syndrome. Scand J Gastroenterol1983; 18: 277–287.
6.
RuddellWSJLosowskyMS: Severe diarrhoea due to small intestinal colonisation during Cimetidine treatment. Br Med J1980; 26: 273.
7.
BeekenWLKanichRE: Bacterial flora of the upper small bowel in Crohn's disease. Gastroenterology1973; 65: 390–397.
8.
GoldsteinFWirtsCWKowlessarOD: Diabetic diarrhea and steatorrhea. Microbiologic and clinical observations. Ann Intern Med1970; 72: 215–218.
9.
McEvoyADuttonJJamesOFW: Bacterial contamination of the small intestine is an important cause of occult malabsorption in the elderly. Br Med J1983; 287: 789–793.
10.
CorazzaGRMenozziMGVairaD: A simpler and more rapid approach to the diagnosis of small bowel bacterial overgrowth. Ital J Gastoenterol1985; 17: 182.
11.
BanwellJGYangP: Bacterial overgrowth syndrome. In: Current Therapy in Gastroenterology and Liver Disease, vol. 2 (BaylessTM, ed.). Philadelphia: BC Decker, 1986; pp 156–160.
12.
KingCEToskesPP: Small intestine bacterial overgrowth. Gastroenterology1979; 76: 1035–1055.
13.
VenturiniAP: Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy1983; 29: 1–3.
14.
VinciMGattoAGiglioA: Double-blind clinical trial on infectious diarrhoea therapy: rifaximin versus placebo. Curr Ther Res1984; 36: 92–99.
15.
LamannaAOrsiA: In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia1984; 6: 365–367.
